Til hovedinnhold
Norli Bokhandel

Real-World Evidence in Drug Development and Evaluation

2022, Heftet, Engelsk

649,-

Bestillingsvare – sendes normalt innen 10-14 virkedager
  • Ikke tilgjengelig for hent i butikk

Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field.

Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions.

Features

  • Provides the first book and a single source of information on RWE in drug development
  • Covers a broad array of topics on outcomes- and value-based RWE assessments
  • Demonstrates proper Bayesian application and causal inference for real-world data (RWD)
  • Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insights
  • Offers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise

Produktegenskaper

  • Bidragsyter

    Binbing Yu (Redaktør) ; Harry Yang (Redaktør)
  • Forlag/utgiver

    Chapman & Hall/CRC
  • Format

    Heftet
  • Språk

    Engelsk
  • Utgivelsesår

    2022
  • Antall sider

    178
  • Serienavn

    Chapman & Hall/CRC Biostatistics Series
  • Utgivelsesdato

    29.08.2022
  • EAN

    9780367637019

Kundeanmeldelser

Frakt og levering